Quantumzyme CORP 10-Q quarterly reports

Quantum Genesis AI Corp. reports a net loss of $24,912 for Q3 2026, with significant operating expenses and a substantial accumulated deficit, raising going concern doubts.

Quantum Genesis AI Corp. files an amendment to its Form 10-Q for the period ended January 31, 2026, to provide additional disclosure regarding intellectual property and formalize rights acquired via an asset purchase agreement.

Quantumzyme Corp. files an amendment to its Form 10-Q for the period ended October 31, 2025, to provide additional disclosure on intellectual property and rights formalized from a prior asset purchase agreement.

Quantum Genesis AI Corp. reported a significant net loss of $4.38 million for the six months ended January 31, 2026, raising substantial doubt about its ability to continue as a going concern.

Quantumzyme Corp. reported a net loss of $49,868 and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Quantumzyme Corp. reported a significant net loss and a substantial accumulated deficit for the nine months ended April 30, 2025, raising substantial doubt about its ability to continue as a going concern.